Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

Similar articles for PubMed (Select 23291631)

1.

Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma.

Chen L, Li Y, Lin CH, Chan TH, Chow RK, Song Y, Liu M, Yuan YF, Fu L, Kong KL, Qi L, Li Y, Zhang N, Tong AH, Kwong DL, Man K, Lo CM, Lok S, Tenen DG, Guan XY.

Nat Med. 2013 Feb;19(2):209-16. doi: 10.1038/nm.3043. Epub 2013 Jan 6.

2.

A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma.

Chan TH, Lin CH, Qi L, Fei J, Li Y, Yong KJ, Liu M, Song Y, Chow RK, Ng VH, Yuan YF, Tenen DG, Guan XY, Chen L.

Gut. 2014 May;63(5):832-43. doi: 10.1136/gutjnl-2012-304037. Epub 2013 Jun 13.

3.

RNA editome imbalance in hepatocellular carcinoma.

Qi L, Chan TH, Tenen DG, Chen L.

Cancer Res. 2014 Mar 1;74(5):1301-6. doi: 10.1158/0008-5472.CAN-13-3485. Epub 2014 Feb 20. Review.

4.

Hepatocellular carcinoma: transcriptome diversity regulated by RNA editing.

Li Y, Chen L, Chan TH, Guan XY.

Int J Biochem Cell Biol. 2013 Aug;45(8):1843-8. doi: 10.1016/j.biocel.2013.05.033. Epub 2013 Jun 4. Review.

PMID:
23748106
5.

Adenosine-to-inosine RNA editing mediated by ADARs in esophageal squamous cell carcinoma.

Qin YR, Qiao JJ, Chan TH, Zhu YH, Li FF, Liu H, Fei J, Li Y, Guan XY, Chen L.

Cancer Res. 2014 Feb 1;74(3):840-51. doi: 10.1158/0008-5472.CAN-13-2545. Epub 2013 Dec 3.

6.

RNA over-editing of BLCAP contributes to hepatocarcinogenesis identified by whole-genome and transcriptome sequencing.

Hu X, Wan S, Ou Y, Zhou B, Zhu J, Yi X, Guan Y, Jia W, Liu X, Wang Q, Qi Y, Yuan Q, Huang W, Liao W, Wang Y, Zhang Q, Xiao H, Chen X, Huang J.

Cancer Lett. 2015 Feb 28;357(2):510-9. doi: 10.1016/j.canlet.2014.12.006. Epub 2014 Dec 8.

PMID:
25499081
7.

ADAR2-mediated editing of miR-214 and miR-122 precursor and antisense RNA transcripts in liver cancers.

Liu WH, Chen CH, Yeh KH, Li CL, Wu YJ, Chen DS, Chen PJ, Yeh SH.

PLoS One. 2013 Dec 27;8(12):e81922. doi: 10.1371/journal.pone.0081922. eCollection 2013.

8.

Targeted disruption of S100P suppresses tumor cell growth by down-regulation of cyclin D1 and CDK2 in human hepatocellular carcinoma.

Kim JK, Jung KH, Noh JH, Eun JW, Bae HJ, Xie HJ, Ahn YM, Ryu JC, Park WS, Lee JY, Nam SW.

Int J Oncol. 2009 Dec;35(6):1257-64.

PMID:
19885547
9.

A polymorphism that delays fibrosis in hepatitis C promotes alternative splicing of AZIN1, reducing fibrogenesis.

Paris AJ, Snapir Z, Christopherson CD, Kwok SY, Lee UE, Ghiassi-Nejad Z, Kocabayoglu P, Sninsky JJ, Llovet JM, Kahana C, Friedman SL.

Hepatology. 2011 Dec;54(6):2198-207. doi: 10.1002/hep.24608.

10.

The large form of ADAR 1 is responsible for enhanced hepatitis delta virus RNA editing in interferon-alpha-stimulated host cells.

Hartwig D, Schütte C, Warnecke J, Dorn I, Hennig H, Kirchner H, Schlenke P.

J Viral Hepat. 2006 Mar;13(3):150-7.

PMID:
16475990
11.

Ornithine decarboxylase antizyme inhibitor 2 regulates intracellular vesicle trafficking.

Kanerva K, Mäkitie LT, Bäck N, Andersson LC.

Exp Cell Res. 2010 Jul 1;316(11):1896-906. doi: 10.1016/j.yexcr.2010.02.021. Epub 2010 Feb 24.

PMID:
20188728
12.
13.

Upregulator of cell proliferation predicts poor prognosis in hepatocellular carcinoma and contributes to hepatocarcinogenesis by downregulating FOXO3a.

Xie C, Song LB, Wu JH, Li J, Yun JP, Lai JM, Xie DY, Lin BL, Yuan YF, Li M, Gao ZL.

PLoS One. 2012;7(7):e40607. doi: 10.1371/journal.pone.0040607. Epub 2012 Jul 16.

14.

RNA editing by ADAR2 is metabolically regulated in pancreatic islets and beta-cells.

Gan Z, Zhao L, Yang L, Huang P, Zhao F, Li W, Liu Y.

J Biol Chem. 2006 Nov 3;281(44):33386-94. Epub 2006 Sep 6.

15.

Neuron-derived orphan receptor 1 promotes proliferation of quiescent hepatocytes.

Vacca M, Murzilli S, Salvatore L, Di Tullio G, D'Orazio A, Lo Sasso G, Graziano G, Pinzani M, Chieppa M, Mariani-Costantini R, Palasciano G, Moschetta A.

Gastroenterology. 2013 Jun;144(7):1518-1529.e3. doi: 10.1053/j.gastro.2013.02.027. Epub 2013 Feb 24.

PMID:
23462179
16.

Regulation of cell proliferation by the antizyme inhibitor: evidence for an antizyme-independent mechanism.

Kim SW, Mangold U, Waghorne C, Mobascher A, Shantz L, Banyard J, Zetter BR.

J Cell Sci. 2006 Jun 15;119(Pt 12):2583-91. Epub 2006 May 30.

17.

Altered adenosine-to-inosine RNA editing in human cancer.

Paz N, Levanon EY, Amariglio N, Heimberger AB, Ram Z, Constantini S, Barbash ZS, Adamsky K, Safran M, Hirschberg A, Krupsky M, Ben-Dov I, Cazacu S, Mikkelsen T, Brodie C, Eisenberg E, Rechavi G.

Genome Res. 2007 Nov;17(11):1586-95. Epub 2007 Oct 1.

18.

Detection of ornithine decarboxylase messenger RNA in human hepatocellular carcinoma by in situ hybridization.

Gan FY, Gesell MS, Moshier JA, Alousi M, Luk GD.

Epithelial Cell Biol. 1992 Jan;1(1):13-7.

PMID:
1339180
19.

Adenosine-to-inosine RNA editing meets cancer.

Dominissini D, Moshitch-Moshkovitz S, Amariglio N, Rechavi G.

Carcinogenesis. 2011 Nov;32(11):1569-77. doi: 10.1093/carcin/bgr124. Epub 2011 Jun 29. Review.

20.

RNA editing enters the limelight in cancer.

Gallo A.

Nat Med. 2013 Feb;19(2):130-1. doi: 10.1038/nm.3072. No abstract available.

PMID:
23389604
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk